No Data
No Data
First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
Express News | Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
No Data
Mr Brooks : Thank you. You are amazing. !!!
Trytosaveabit : As you know I’ve been waiting for this 510 clearance! I know most don’t like it! And admittedly the chart and volume are not looking good! Hehehe! But I really like, have like and continue to like MOVE! Hehehe! People don’t realize just how superior this is over the junk you can just buy on Amazon! Hehehe
Jaguar8 OP Trytosaveabit : Yes it took forever for this EvieRing to get cleared even with superior results . Glad they had it
Trytosaveabit Jaguar8 OP : Yup yup! I knew at one point you felt as I do! Not sure where you stand these days? Hehehe.
Jaguar8 OP Trytosaveabit : It was just parked on my FDA watchlist and waited forever
View more comments...